| Affiliation: | 1. Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY, USA !["ORCID]("//:0" "\"ORCID") https://orcid.org/0000-0002-3945-6828;2. Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA, USA https://orcid.org/0000-0002-8104-2450;3. Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, USA https://orcid.org/0000-0001-5973-3477;4. Division of Rheumatology, Department of Medicine, Washington University School of Medicine , St. Louis, MO, USA https://orcid.org/0000-0001-8549-6559;5. Department of Rheumatology, Sorbonne University, INSERM CRSA, AP-HP , Paris, France https://orcid.org/0000-0001-8252-7815;6. Division of Rheumatology, Mayo Clinic , Rochester, MN, USA https://orcid.org/0000-0003-1749-5719 |
| Abstract: | ABSTRACT Introduction Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific community and the public. |
!["ORCID]({"type":"image","src":"/templates/jsp/images/orcid.png"} "\"ORCID")
https://orcid.org/0000-0002-3945-6828;2. Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA, USA